BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharmaceuticals Inc. demonstrates a promising financial outlook driven by the robust sales performance of its product, Orladeyo, which achieved $156.8 million in Q2 2025, reflecting a quarter-over-quarter growth of 17% and a year-over-year increase of 45%. The company anticipates Orladeyo's sales will reach between $580 million and $600 million in 2025, positioning BioCryst to maintain a cash flow-positive and profitable status on a non-GAAP basis. The ongoing expansion of the prescriber base and growing new patient starts indicate sustained growth potential for the company's offerings beyond five years post-launch.

The financial outlook for BioCryst Pharmaceuticals appears pessimistic due to a slight decline in Orladeyo prescriber numbers from 69 in 2Q25 to 64 in 3Q25, indicating potential challenges in maintaining growth momentum. Additionally, the anticipated decrease in Orladeyo sales in 4Q25 is expected as a result of the divestment of its EU business, which could further impact revenue streams. Despite the absence of immediate competitive pressures from newly launched HAE prophylactics, the overall sales performance and market strategy raise concerns about the company's future profitability and market position.